Table 3Mixed-treatment comparisons analysis of discontinuations from trialsa

AsenapineClozapineIloperidoneOlanzapineQuetiapinePaliperidoneRisperidoneZiprasidone
Aripiprazole1.01 (0.67 – 1.56)0.71 (0.48 – 1.02)1.51 (0.92 – 2.61)0.70 (0.53 – 0.90)1.12 (0.80 – 1.51)0.95 (0.55 – 1.85)0.96 (0.73 – 1.29)1.23 (0.87 – 1.79)
AsenapineNA0.70 (0.43 – 1.09)1.50 (0.85 – 2.90)0.48 (0.69 – 0.98)1.10 (0.74 – 1.64)0.95 (0.50 – 1.77)0.96 (0.67 – 1.39)1.22 (0.79 – 1.87)
ClozapineNA2.15 (1.27 – 3.78)0.98 (0.74 – 1.29)1.58 (1.16 – 2.16)1.40 (0.77 – 2.53)1.40 (1.01 – 1.89)1.75 (1.23 – 2.49)
IloperidoneNA0.46 (0.29 – 0.72)0.73 (0.45 – 1.17)0.63 (0.32 – 1.28)0.64 (0.40 – 0.99)0.82 (0.49 – 1.34)
OlanzapineNA1.61 (1.30 – 1.95)1.39 (0.84 – 2.41)1.40 (1.19 – 1.67)1.78 (1.40 – 2.27)
QuetiapineNA0.87 (0.52 – 1.50)0.87 (0.71 – 1.07)1.11 (0.84 – 1.50)
PaliperidoneNA1.00 (0.57 – 1.68)1.29 (0.72 – 2.17)
RisperidoneNA1.27 (0.99 – 1.66)
ZiprasidoneNA

Abbreviations: NA, not available.

a

Adjusted odds ratios (95% confidence intervals) for column compared with row calculated using a fixed-effects model.

b

Adjusted for dose level (low, medium, high) within allocated group and duration of study.

Adjusted odds ratios (95% confidence intervals) for column compared with row calculated using a fixed-effects model.

From: Results

Cover of Drug Class Review: Atypical Antipsychotic Drugs
Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].
McDonagh M, Peterson K, Carson S, et al.
Portland (OR): Oregon Health & Science University; 2010 Jul.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.